A long sought-after goal across a wide range of healthcare specialties is to devise strategies that enhance patient care and simultaneously reduce expenses. Inflammatory diseases and chronic syndromes currently impose an immense social and economic burden on society in terms of both direct and indirect healthcare costs. While published annual direct costs attributable to the reviewed group of inflammatory diseases and syndromes is currently greater than $90B ($35B MS, IBD, RA and $55B IBS, FMS), this estimation understates the true cost potential. Enhanced diagnostic criteria coupled with additional technological innovation to identify inflammatory conditions earlier is necessary and in the best interest of all healthcare stakeholders. Through unique analysis of financial cost drivers, this review identifies opportunities to improve clinical outcomes and help control these disease-related costs by 20% or more.